Drug Insights

How to Effectively Search for BuSpar on Synapse

23 February 2024
2 min read

BuSpar® (buspirone hydrochloride) is an antianxiety agent that is not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs. Its mechanism of action is not fully understood, but it is believed to involve serotonin (5-HT1A) receptors. BuSpar is indicated for the management of anxiety disorders or the short-term relief of anxiety symptoms(Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic) . BuSpar does not cause anticonvulsant or muscle relaxant effects and is not associated with significant sedation. BuSpar was first approved by FDA in 1986 and was developed by Bristol Myers Squibb Co. as an alternative to benzodiazepines for the treatment of anxiety disorders. Click on the image below to begin the exploration journey of BuSpar through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

EU Approves Pfizer's VELSIPITY® for Moderate to Severe Ulcerative Colitis
Latest Hotspot
3 min read
EU Approves Pfizer's VELSIPITY® for Moderate to Severe Ulcerative Colitis
23 February 2024
EU Regulatory Body Sanctions Pfizer's VELSIPITY® Use in Individuals with Moderate to Severe Ulcerative Colitis Cases.
Read →
Exploring Disitamab Vedotin's R&D successes and its clinical results at the 2024 ASCO_GU
Exploring Disitamab Vedotin's R&D successes and its clinical results at the 2024 ASCO_GU
23 February 2024
The latest ASCO_GU 2024 update summarized new clinical findings on disitamab vedotin and toripalimab as an innovative neoadjuvant therapy for HER2+ advanced local MIBC patients.
Read →
FDA Endorses Xolair as the Sole Treatment for Food Allergies in Both Kids and Grown-ups
Latest Hotspot
3 min read
FDA Endorses Xolair as the Sole Treatment for Food Allergies in Both Kids and Grown-ups
23 February 2024
Genentech announced that the US FDA has approved Xolair (omalizumab) for reducing allergic reactions.
Read →
Your Ultimate Guide to Finding Diclofenac sodium on Synapse
Drug Insights
2 min read
Your Ultimate Guide to Finding Diclofenac sodium on Synapse
23 February 2024
Diclofenac sodium, a benzene-acetic acid derivative, is a nonsteroidal anti-inflammatory drug (NSAID) ,has analgesic, anti-inflammatory, and antipyretic properties.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.